Pharmacolog Appoints New Development Manager

Pharmacolog appoints Jörgen Höjdmo as the new Development Manager. Jörgen has extensive experience in leading advanced development projects and is one of the main architects of the company’s current DrugLog® systems.

As a development manager Jörgen will be responsible for the company’s product development and manage internal and external resources. Jörgen Höjdmo has a MSc in Engineering Physics and more than 20 years of experience in technology and software development. He has also worked as CEO of Digital Diary AB, which later was sold to FormPipe AB 2005 where Jorgen continued to work as a Partner Manager until 2007. The last 10 years has Jörgen mainly worked as a consultant in management and advanced technology development and lead for 6 years an extensive project for the Swedish Armed Forces. Jörgen has since 2008 also been involved in Pharmacolog development of DrugLog®.

CEO Mats Högberg commented. “We are very pleased that Jorgen decided to accept the role as development manager. As we are starting new exciting development projects, it is essential that we have someone with the experience and technical expertise to lead our team. Jörgen’s unique competence in analytic technology combined with experience in managing development projects will mean a lot for our ability to quickly realize new innovations within our vision of individualized care and optimized drug use. ”

Read the official press release (Swedish) here: Pharmacolog tillsätter ny utvecklingschef.

Pharmacolog signs agreement with B. Braun S.A.

Pharmacolog has entered into an agreement with B. Braun Medical S.A Spain concerning exclusive distribution of DrugLog® on the Spanish market. The agreement also considers the future integration of DrugLog® with one of the company’s software Oncology technologies.

Braun Medical S.A. Spain is a company within the B. Braun Group engaged, among other activities, in the product development in the field of Injectable Drug Delivery. The area includes developing new solutions for managing the entire process of chemotherapy with cytotoxic drugs, from prescription to patient infusion. The agreement signed between Pharmacolog and B. Braun Medical Spain means that B. Braun acts as an exclusive distrib...

Pharmacolog kallar till bolagsstämma

Aktieägarna i Pharmacolog i Uppsala AB (publ), 556723-6418 (”Bolaget”), kallas härmed till årsstämma torsdagen den 15 mars 2018 kl. 16.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.

Anmälan m.m.

Aktieägare som önskar delta vid årsstämman skall:

–    dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 9 mars 2018, och

–    dels anmäla sin avsikt att närvara senast kl. 16.00 fredagen den 12 mars 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till

Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (ell...

Continued negotiations with international MedTech Group

In a press release published September 6 2017, the Company announced that it had signed a letter of intent with a major MedTech Group about entering into a long-term cooperation. The goal was to have an agreement signed before the end of 2017, but the schedule has shifted slightly.

The letter of intent meant that the parties were working to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare wards. Work on establishing a formal agreement is in progress but the schedule has shifted slightly, and the goal is to have the agreement clear during the first quar...

Extended collaboration with Uppsala University regarding dosage of antibiotics

Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.

The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.

Hans Dahlin, Research Director and Founder, comments: R...